Gilead Sciences (NASDAQ: GILD) recently received a number of ratings updates from brokerages and research firms:

  • 7/17/2017 – Gilead Sciences was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $79.00 price target on the stock. According to Zacks, “Gilead’s HIV franchise has been gaining momentum of late. Rapid adoption of TAF-based regimens, representing 42% of total Gilead HIV prescription volume, following the launch of Genvoya and the launches of Odefsey and Descovy in 2016 boosted results. Strong uptake for Truvada for use in the pre-exposure prophylaxis setting should also boost sales.The company saw a significant uptick in PrEP usage in 2017 with an estimated 125,000 patients using Truvada by the end of the first quarter. The company submitted a NDA to the FDA for single tablet regimen for bictegravir. However, Gilead will lose exclusivity for Viread in 2017 in some countries outside the U.S. which should impact sales. In addition, the HCV franchise continues to be under competitive and pricing pressure leading to a decline in Harvoni and Sovaldi sales.”
  • 7/13/2017 – Gilead Sciences had its “outperform” rating reaffirmed by analysts at Robert W. Baird. They now have a $87.00 price target on the stock.
  • 7/11/2017 – Gilead Sciences had its “hold” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $80.00 price target on the stock.
  • 7/11/2017 – Gilead Sciences had its “equal weight” rating reaffirmed by analysts at Morgan Stanley.
  • 7/5/2017 – Gilead Sciences had its “outperform” rating reaffirmed by analysts at Cowen and Company. They now have a $90.00 price target on the stock.
  • 7/4/2017 – Gilead Sciences had its “buy” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $82.00 price target on the stock.
  • 7/4/2017 – Gilead Sciences had its “overweight” rating reaffirmed by analysts at J P Morgan Chase & Co. They now have a $82.00 price target on the stock.
  • 6/26/2017 – Gilead Sciences was upgraded by analysts at Vetr from a “buy” rating to a “strong-buy” rating. They now have a $83.66 price target on the stock.
  • 6/23/2017 – Gilead Sciences is now covered by analysts at Deutsche Bank AG. They set a “buy” rating and a $79.00 price target on the stock.
  • 6/22/2017 – Gilead Sciences was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating.
  • 6/22/2017 – Gilead Sciences had its “market perform” rating reaffirmed by analysts at Leerink Swann.
  • 6/21/2017 – Gilead Sciences was downgraded by analysts at Vetr from a “strong-buy” rating to a “buy” rating. They now have a $75.40 price target on the stock.
  • 6/16/2017 – Gilead Sciences had its “outperform” rating reaffirmed by analysts at William Blair.
  • 6/2/2017 – Gilead Sciences was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating.

Shares of Gilead Sciences, Inc. (NASDAQ:GILD) traded up 0.82% during midday trading on Monday, hitting $71.15. 7,612,423 shares of the company were exchanged. Gilead Sciences, Inc. has a one year low of $63.76 and a one year high of $88.85. The firm has a market cap of $92.97 billion, a P/E ratio of 7.52 and a beta of 1.20. The company’s 50 day moving average price is $66.03 and its 200 day moving average price is $68.95.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Tuesday, May 2nd. The biopharmaceutical company reported $2.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.18 by $0.02. Gilead Sciences had a return on equity of 76.64% and a net margin of 43.42%. The business had revenue of $6.51 billion for the quarter, compared to analyst estimates of $6.66 billion. Equities analysts expect that Gilead Sciences, Inc. will post $8.37 EPS for the current year.

The company also recently declared a quarterly dividend, which was paid on Thursday, June 29th. Stockholders of record on Friday, June 16th were paid a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a dividend yield of 2.92%. The ex-dividend date of this dividend was Wednesday, June 14th. Gilead Sciences’s dividend payout ratio (DPR) is presently 21.99%.

In other Gilead Sciences news, Director John Francis Cogan sold 9,943 shares of the stock in a transaction dated Tuesday, May 9th. The stock was sold at an average price of $67.25, for a total value of $668,666.75. Following the transaction, the director now owns 47,562 shares of the company’s stock, valued at $3,198,544.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Gregg H. Alton sold 5,000 shares of the stock in a transaction dated Monday, July 3rd. The shares were sold at an average price of $71.06, for a total value of $355,300.00. Following the completion of the transaction, the executive vice president now directly owns 102,988 shares in the company, valued at approximately $7,318,327.28. The disclosure for this sale can be found here. Insiders have sold 88,276 shares of company stock worth $6,230,610 in the last ninety days. 1.30% of the stock is currently owned by insiders.

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Receive News & Ratings for Gilead Sciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.